证券日报网讯 2月13日，禾元生物在互动平台回答投资者提问时表示，公司药品奥福民®已覆盖湖北省 多家三甲医院，例如武汉大学中南医院、湖北省人民医院等，可就近咨询或查询。药品价格严格执行全 国挂网价格政策，具体价格以各医院实际公示为准。 （文章来源：证券日报） ...

Core Viewpoint - The keyword for the stock market in 2025 is expected to be "innovative drugs," with significant stock price increases driven by the potential of in-development innovative drugs and BD (business development) transactions rather than traditional revenue from already marketed drugs [1] Group 1: BD Transactions - In 2025, China's innovative drug BD transaction total exceeded $100 billion, with notable orders reaching $10 billion, and upfront payments from multinational pharmaceutical companies reaching a new high of $1.25 billion [1] - Landmark transactions include a $13 billion collaboration between Qihuang Dejian and Biohaven/AimedBio in January, marking a milestone for China's ADC technology [2] - In May, 3SBio's deal with Pfizer exceeded $6 billion, setting a record for upfront payments in China at $1.25 billion, highlighting the value of both first-in-class and fast-follow drugs [2] - In July, a $12 billion strategic partnership between Hengrui Medicine and GlaxoSmithKline showcased the depth of early-stage pipelines in leading Chinese pharmaceutical companies [2] - In October, Innovent Biologics and Takeda's collaboration worth $11.4 billion included a cost-sharing model for global R&D, enhancing operational capabilities for future international ventures [2] Group 2: Milestone Payments and Emerging Fields - Several past BD transactions reached milestone payments in 2025, including a $300 million payment to China National Pharmaceutical's subsidiary from Merck and a $250 million payment to Bairui Tianheng from Bristol-Myers Squibb [3] - The focus of BD transactions is shifting from oncology to other therapeutic areas, with autoimmune diseases, metabolism, and central nervous system disorders emerging as new hot fields [3] - Notable deals include the global rights licensing of BTK inhibitor Orelabrutinib for multiple sclerosis by Nocera Biopharma, with a potential total transaction value exceeding $2 billion [3] - The metabolic field is gaining traction, driven by global weight loss trends, with several companies entering into licensing agreements for GLP-1 targeted drugs [3] Group 3: Independent Clinical Trials and Regulatory Approvals - Numerous innovative drug companies in China are advancing their own overseas clinical trials, achieving significant progress [4] - In early 2025, Dize Pharmaceutical's lung cancer targeted drug received priority review from the FDA and was approved in July, becoming the first globally innovative drug independently developed in China to gain approval in the U.S. [4] - Other advancements include breakthrough therapy designations for CS0159 by Kexi Kedi and a Phase III trial approval for a recombinant human albumin injection by Heyuan Biopharma [4] - These developments indicate that the Chinese innovative drug industry is becoming a significant force in global innovation, transitioning from fast-following to original innovation and integrating deeply into the global value chain [4]

公司的技术发展并非静态。杨代常透露，在科研层面，表达量提升的"天花板"尚未触及，预计还有继续提升空间，更高表达量的品系已在研发 中。 "禾元生物正处于从技术破壁转向市场破局的关键阶段。"近日，公司董事长杨代常在接受证券时报记者专访时指出，当前重点任务是加速推进奥 福民的市场准入与销售放量，并力争早日实现盈利，构建研发与商业化正向循环。作为硬科技创新的代表，禾元生物上市进程反映出资本市场对 原创生物医药企业的持续支持，为同类技术驱动型公司提供了重要范本。 先瞄准国产替代空间 在生物医药领域，人血清白蛋白的临床使用历史已超过40年，但其生产始终无法摆脱对血浆的依赖。全球范围内，通过基因重组技术实现规模化 替代的尝试屡屡受挫，核心瓶颈在于缺乏一个能同时满足"安全、可及、可产业化、可规模化"要求的技术体系。杨代常指出，许多生物药都已成 功商业化，但白蛋白在过去未能成功，根本原因是"缺乏支撑性的体系"。 杨代常介绍，公司的重组蛋白高效表达平台历经三代迭代，目前重组蛋白表达量水平可达30g/kg，胚乳特异性启动子改造等专利技术是核心壁 垒；蛋白纯化平台可使纯度达99.9999%，同时纯化成本较微生物体系有明显降低。他强调 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 作为一家通过科创板第五套上市标准登陆资本市场的未盈利生物医药企业，禾元生物（688765.SH）自 上市以来便备受关注。然而，随着近期公司发布2025年业绩预告，其持续扩大的亏损、紧绷的现金流、 核心产品商业化存疑以及信息披露的争议，正使其成为观察未盈利科创企业生存现状的一个典型样本。 另一个值得关注的细节是：公司上市不到一个月即为全体董事及高管购买责任险，虽称意在完善风控体 系，却也侧面透露出对运营风险的自我预警。在持续"失血"的财务状况下，此类支出虽金额不大，仍引 发市场对其财务纪律的审视。 03核心产品商业化与信息披露隐忧 作为未盈利生物科技公司，禾元生物的未来很大程度上系于其核心在研产品HY1001的商业化前景。然 而，该产品的市场预期却在IPO问询过程中悄然"缩水"——公司对2026年至2030年的收入预测从72.55亿 元下调至54.70亿元，累计调减近18亿元，却未在招股书中给出明确解释。 与此同时，该产品仍缺乏商业化验证。其在I期临床试验中曾出现严重不良事件，虽被评估可能与胆石 症相关，但未完全排除与药物本身的关联。公司在最新招股书中亦坦言"稻 ...

证券日报网讯 2月3日，禾元生物在互动平台回答投资者提问时表示，根据信息披露相关规则，公司会 在定期报告中披露法定要求的股东数量信息。如需了解公司其他特定时点的股东人数，请提供本人持股 证明及有效身份证明等材料至公司邮箱ir@oryzogen.com，公司将核实股东身份后回复。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问一下，上次您说部分设备已完成调试，是不是已 经提供了新增产能？而且市场是供不应求的状态？ 禾元生物（688765.SH）2月3日在投资者互动平台表示，公司120吨重组人白蛋白生产线预计2026年建 成，新增产能需设备调试完成且经药监局GMP验证通过后投入生产。公司药品奥福民®于2025年7月获 批上市并进入市场导入阶段，医院准入、渠道铺货等工作正稳步推进。 ...

（编辑 丛可心） 证券日报网讯 1月29日，禾元生物在互动平台回答投资者提问时表示，公司药品奥福民®（重组人白蛋 白注射液）自上市以来已完成各省药品招采目录挂网工作，全国各省份已陆续销售。公司已预约2026年 4月28日披露2025年年度报告，有关销售具体情况敬请留意后续公告。 ...

Core Viewpoint - He Yuan Bio has successfully completed the listing of its drug, Aofumin (recombinant human albumin injection), in the procurement catalog across various provinces in China, and sales have commenced nationwide [1] Group 1 - The company has responded to investor inquiries regarding the sales status of Aofumin, indicating that it is now available in multiple provinces [1] - Aofumin's sales performance will be detailed in the upcoming annual report, scheduled for release on April 28, 2026, covering the fiscal year 2025 [1]

Group 1 - The company forecasts a total profit loss of between -167 million to -143 million yuan for the year 2025, with a net profit attributable to the parent company also expected to be in the same range [3][4] - The expected net profit attributable to the parent company, after deducting non-recurring gains and losses, is projected to be between -191 million to -162 million yuan [4] - The anticipated operating revenue for 2025 is estimated to be between 45 million to 50 million yuan, representing a year-on-year increase of 78.46% to 98.29% [4] Group 2 - In the same period last year, the company reported a total profit loss of -151.37 million yuan and a net profit attributable to the parent company of -151.37 million yuan [6] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -166.75 million yuan [6] - The operating revenue for the previous year was 25.22 million yuan [8] Group 3 - The increase in sales revenue is attributed to the market introduction of the product "Aofumin" (recombinant human albumin injection) [9] - The production line for the related product is currently in a ramp-up phase, with capacity expected to gradually increase [9] - The company continues to maintain high levels of investment in research and development [10]

证券日报网讯 1月28日，禾元生物发布公告称，公司预计2025年年度实现营业收入为4，500万元到5， 000万元，同比增加78.46%到98.29%，预计归属于母公司所有者的净利润为-16，700万元到-14，300万 元。 （编辑 袁冠琳） ...